CytomX Therapeutics, Inc. - 8-K Filing
CytomX Therapeutics reported Q1 2026 financial results with $10.3 million in revenue and $346.7 million in cash, cash equivalents, and investments as of March 31, 2026. The company announced positive data from the Phase 1 dose expansion study of Varseta-M in advanced colorectal cancer and plans for additional data updates in 2H 2026. CytomX also completed an equity offering in March 2026, raising $250 million in gross proceeds. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CTMX